Production (Stage)
Integrated Biopharma, Inc.
INBP
$0.292
$0.0020.69%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,181.03% | 341.04% | 841.38% | 429.41% | -108.17% |
| Total Depreciation and Amortization | 4.66% | 5.00% | 5.34% | 5.81% | 12.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.85% | 142.28% | 41.51% | -14.49% | 145.39% |
| Change in Net Operating Assets | -35.69% | 59.65% | -3,285.00% | -146.36% | -143.87% |
| Cash from Operations | 2,359.65% | 1,106.52% | -81.52% | -23.46% | -101.11% |
| Capital Expenditure | 18.35% | -500.00% | -449.04% | -376.72% | -219.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 18.16% | -506.32% | -476.77% | -398.20% | -228.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 56.10% | 31.71% | 4.88% | 69.12% | 98.14% |
| Issuance of Common Stock | 38.46% | 38.46% | -100.00% | -- | -51.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | 64.29% | -39.29% | 78.68% | 98.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 284.87% | 589.80% | -122.65% | -63.35% | -122.47% |